Nodify XL2® testing helps identify patients with likely benign lung nodules and supports clinical decision-making so physicians can more confidently identify patients who have a reduced risk of malignancy and may avoid unnecessary invasive procedures.
Learn more about:
The Nodify XL2 test is intended for patients with incidental lung nodules:
1. Swensen SJ, Silverstein MD, Ilstrup DM, et. al. "The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules." Arch Intern Med. 1997 Apr 28; 157(8):849-55.
2. Silvestri G et al. "Assessment of plasma proteomics biomarkers ability to distinguish benign from malignant lung nodules." CHEST. 2018 Sept. 154(3):491-500.